LOWELL S. YOUNG, M.D.
One of the more sobering realities of clinical investigation is that some innovations that initially appear to be major advances later prove to be of more limited value or become identified with major hazards. This appears to be the case with granulocyte transfusions, a costly form of intervention whose therapeutic and prophylactic benefit to neutropenic patients seemed to have been established by an initial series of controlled clinical trials (1, 2). Earlier enthusiastic reports, however, did not mention the complications of transfusion-associated viral infections. This is an area now being carefully reassessed.
In this issue, Hersman and colleagues (3) have
YOUNG LS. Prophylactic Granulocytes in the Neutropenic Host. Ann Intern Med. ;96:240–242. doi: 10.7326/0003-4819-96-2-240
Download citation file:
Published: Ann Intern Med. 1982;96(2):240-242.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use